Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors (XELBEVOCT)

NCT01203306 Phase 2 UNKNOWN

Well differentiated neuroendocrine (NE) carcinomas have low proliferative activity and conventional chemotherapy is not recommended. Metronomic chemotherapy, i.e. the frequent administration of cytotoxic drugs at low doses, has demonstrated antiangiogenetic properties. Since well differentiated NE carcinomas are highly vascular, there is a rationale for testing metronomic chemotherapy and antiangiogenetic drugs. This is a national, multicenter, phase II study.

Details

Lead sponsor	University of Turin, Italy
Phase	Phase 2
Status	UNKNOWN
Enrolment	42
Start date	2006-01
Completion	2010-12

Conditions

• Neuroendocrine Carcinomas

Interventions

• bevacizumab + octreotide LAR + capecitabine

Primary outcomes

• time to progression — 36 months

Countries

Italy